{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:10Z","timestamp":1791402310672,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00113-2","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:07:12Z","timestamp":1765534032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Invasive fungal infections in hematologic diseases: evidence, challenges, and clinical practice"],"prefix":"10.1007","volume":"60","author":[{"given":"Sung-Yeon","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dukhee","family":"Nho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"11","key":"113_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41579-024-01062-w","volume":"22","author":"GD Brown","year":"2024","unstructured":"Brown GD, Ballou ER, Bates S, Bignell EM, Borman AM, Brand AC, et al. The pathobiology of human fungal infections. Nat Rev Microbiol. 2024;22(11):687\u2013704.","journal-title":"Nat Rev Microbiol"},{"key":"113_CR2","volume-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022."},{"issue":"7","key":"113_CR3","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428\u201338.","journal-title":"Lancet Infect Dis"},{"key":"113_CR4","doi-asserted-by":"publisher","first-page":"832510","DOI":"10.3389\/fmed.2022.832510","volume":"9","author":"F Palmieri","year":"2022","unstructured":"Palmieri F, Koutsokera A, Bernasconi E, Junier P, von Garnier C, Ubags N. Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on Aspergillus spp. Front Med (Lausanne). 2022;9:832510.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"113_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/cid\/ciac623","volume":"76","author":"J Maertens","year":"2023","unstructured":"Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, et al. Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European Organization for Research and Treatment of Cancer. Clin Infect Dis. 2023;76(4):674\u201382.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"113_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348\u201359.","journal-title":"N Engl J Med"},{"issue":"3","key":"113_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","volume":"77","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Infect. 2018;77(3):227\u201334.","journal-title":"J Infect"},{"issue":"1","key":"113_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/cid\/ciae203","volume":"79","author":"CA Boutin","year":"2024","unstructured":"Boutin CA, Durocher F, Beauchemin S, Ziegler D, Abou Chakra CN, Dufresne SF. Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review. Clin Infect Dis. 2024;79(1):151\u201360.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"113_CR9","doi-asserted-by":"publisher","first-page":"ofaf163","DOI":"10.1093\/ofid\/ofaf163","volume":"12","author":"K Ishida","year":"2025","unstructured":"Ishida K, Haraguchi M, Kimura M, Araoka H, Natori A, Reynolds JM, et al. Incidence of breakthrough fungal infections in patients with isavuconazole prophylaxis: a systematic review and meta-analysis. Open Forum Infect Dis. 2025;12(4):ofaf163.","journal-title":"Open Forum Infect Dis"},{"key":"113_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.06.003","author":"U Akova","year":"2025","unstructured":"Akova U, Hicklen R, Lewis RE, Walsh TJ, Kontoyiannis DP. Fungal infections in patients with hematological malignancies in the pre-triazole era: the dawn of a new era in medical mycology. Clin Microbiol Infect. 2025. https:\/\/doi.org\/10.1016\/j.cmi.2025.06.003. Epub ahead of print.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"113_CR11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/jof7100848","volume":"7","author":"P Puerta-Alcalde","year":"2021","unstructured":"Puerta-Alcalde P, Garcia-Vidal C. Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation. J Fungi. 2021;7(10):848. https:\/\/doi.org\/10.3390\/jof7100848.","journal-title":"J Fungi"},{"issue":"34","key":"113_CR12","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","volume":"25","author":"E Robenshtok","year":"2007","unstructured":"Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471\u201389.","journal-title":"J Clin Oncol"},{"issue":"4","key":"113_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"6","key":"113_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2011.08650.x","volume":"153","author":"TR Rogers","year":"2011","unstructured":"Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for hematological malignancies: are we there yet? Br J Haematol. 2011;153(6):681\u201397.","journal-title":"Br J Haematol"},{"issue":"2","key":"113_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3904\/kjim.2011.26.2.220","volume":"26","author":"DG Lee","year":"2011","unstructured":"Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26(2):220\u201352.","journal-title":"Korean J Intern Med"},{"issue":"S1","key":"113_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5045\/br.2022.2022036","volume":"57","author":"H Ahn","year":"2022","unstructured":"Ahn H, Lee R, Cho SY, Lee DG. Advances in prophylaxis and treatment of invasive fungal infections: perspectives on hematologic diseases. Blood Res. 2022;57(S1):101\u201311.","journal-title":"Blood Res"},{"key":"113_CR17","doi-asserted-by":"crossref","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221\u20133230.","DOI":"10.1093\/jac\/dky286"},{"issue":"Suppl 1","key":"113_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"113_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.bbmt.2017.06.012","volume":"23","author":"JK Choi","year":"2017","unstructured":"Choi JK, Cho SY, Yoon SS, Moon JH, Kim SH, Lee JH, et al. Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of \u201cRISK\u201d Study. Biol Blood Marrow Transplant. 2017;23(10):1773\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"113_CR20","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","volume":"95","author":"C Cordonnier","year":"2010","unstructured":"Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762\u20138.","journal-title":"Haematologica"},{"issue":"5","key":"113_CR21","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","volume":"9","author":"J Stemler","year":"2022","unstructured":"Stemler J, de Jonge N, Skoetz N, Sink\u00f3 J, Br\u00fcggemann RJ, Busca A, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022;9(5):e361\u201373.","journal-title":"Lancet Haematol"},{"issue":"24","key":"113_CR22","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.3390\/cancers13246285","volume":"13","author":"R Lee","year":"2021","unstructured":"Lee R, Cho SY, Lee DG, Choi H, Park S, Cho BS, et al. Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis. Cancers (Basel). 2021;13(24):6285.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"113_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ajh.27613","volume":"100","author":"JD Kawedia","year":"2025","unstructured":"Kawedia JD, Rausch CR, Liu X, Qiao W, Dinardo CD, Daver N, et al. Prospective pharmacokinetic evaluation of venetoclax in AML supports re-evaluation of recommended dose adjustments with azole antifungals. Am J Hematol. 2025;100(4):740\u20133.","journal-title":"Am J Hematol"},{"issue":"8","key":"113_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, et al. Primary prophylaxis of invasive fungal diseases in patients with hematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813\u201326.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"113_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","volume":"32","author":"J Lindsay","year":"2019","unstructured":"Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32(6):538\u201345.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"113_CR26","doi-asserted-by":"publisher","first-page":"ofae082","DOI":"10.1093\/ofid\/ofae082","volume":"11","author":"JH Young","year":"2024","unstructured":"Young JH, Andes DR, Ardura MI, Arrieta A, Bow EJ, Chandrasekar PH, et al. Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies. Open Forum Infect Dis. 2024;11(3):ofae082. https:\/\/doi.org\/10.1093\/ofid\/ofae082.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"113_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/myc.12213","volume":"57","author":"G Maschmeyer","year":"2014","unstructured":"Maschmeyer G, Patterson TF. Our 2014 approach to breakthrough invasive fungal infections. Mycoses. 2014;57(11):645\u201351.","journal-title":"Mycoses"},{"issue":"8","key":"113_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/bmt.2011.246","volume":"47","author":"MC Arendrup","year":"2012","unstructured":"Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kibbler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 2012;47(8):1030\u201345.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"113_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14737159.2023.2267977","volume":"23","author":"JD Jenks","year":"2023","unstructured":"Jenks JD, White PL, Kidd SE, Goshia T, Fraley SI, Hoenigl M, et al. An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections. Expert Rev Mol Diagn. 2023;23(12):1135\u201352. https:\/\/doi.org\/10.1080\/14737159.2023.2267977.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"113_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"10020","key":"113_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"4","key":"113_CR32","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"113_CR33","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"113_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","volume":"87","author":"P Puerta-Alcalde","year":"2023","unstructured":"Puerta-Alcalde P, Monz\u00f3-Gallo P, Aguilar-Guisado M, Ramos JC, Laporte-Amarg\u00f3s J, Machado M, et al. Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study. J Infect. 2023;87(1):46\u201353.","journal-title":"J Infect"},{"issue":"2","key":"113_CR35","doi-asserted-by":"publisher","first-page":"106535","DOI":"10.1016\/j.jinf.2025.106535","volume":"91","author":"SY Cho","year":"2025","unstructured":"Cho SY, Wurster S, Jiang Y, Bazinet A, Hui Y, Lewis RE, et al. Blastemia portrays a poor prognosis in acute leukemia patients with invasive pulmonary aspergillosis. J Infect. 2025;91(2):106535.","journal-title":"J Infect"},{"issue":"15","key":"113_CR36","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703\u201329.","journal-title":"Drugs"},{"issue":"25","key":"113_CR37","doi-asserted-by":"publisher","first-page":"00224","DOI":"10.1016\/S1473-3099(25)00224-5","volume":"S1473\u20133099","author":"JA Maertens","year":"2025","unstructured":"Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, et al. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025;S1473\u20133099(25):00224\u20135. https:\/\/doi.org\/10.1016\/S1473-3099(25)00224-5. Epub ahead of print.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"113_CR38","doi-asserted-by":"publisher","first-page":"e0141922","DOI":"10.1128\/aac.01419-22","volume":"67","author":"JA Vazquez","year":"2023","unstructured":"Vazquez JA, Pappas PG, Boffard K, Paruk F, Bien PA, Tawadrous M, et al. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial. Antimicrob Agents Chemother. 2023;67(5):e0141922.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"113_CR39","doi-asserted-by":"publisher","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","volume":"64","author":"S Alkhazraji","year":"2020","unstructured":"Alkhazraji S, Gebremariam T, Alqarihi A, Gu Y, Mamouei Z, Singh S, et al. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. Antimicrob Agents Chemother. 2020;64(3):e01735.","journal-title":"Antimicrob Agents Chemother"},{"key":"113_CR40","doi-asserted-by":"publisher","unstructured":"Cass LMR, Ayrton J, Br\u00fcggemann RJ, Moore J, Martin U, Grey L, Hyman M, Berman L. In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent. J Antimicrob Chemother. 2025:dkaf384. https:\/\/doi.org\/10.1093\/jac\/dkaf384. Epub ahead of print.","DOI":"10.1093\/jac\/dkaf384"},{"issue":"8","key":"113_CR41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","volume":"79","author":"LL Benitez","year":"2019","unstructured":"Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. Drugs. 2019;79(8):833\u201353.","journal-title":"Drugs"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00113-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T07:02:11Z","timestamp":1766646131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00113-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["113"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00113-2","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}